
Bristol-Myers Squibb Company BMY
$ 58.23
-2.07%
Annual report 2025
added 02-11-2026
Bristol-Myers Squibb Company Operating Cash Flow 2011-2026 | BMY
Annual Operating Cash Flow Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.2 B | 15.2 B | 13.9 B | 13.1 B | 16.2 B | 14.1 B | 8.21 B | 7.07 B | 5.28 B | 3.06 B | 2.1 B | 3.15 B | 3.54 B | 6.94 B | 4.84 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.2 B | 2.1 B | 8.71 B |
Quarterly Operating Cash Flow Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.95 B | - | - | 2.83 B | - | - | 2.97 B | - | 9.76 B | - | 3.81 B | - | 12.2 B | - | 3.82 B | - | 10.7 B | 8.43 B | 3.94 B | - | 6.03 B | 3.47 B | 1.39 B | - | 3.51 B | 2.23 B | 1.18 B | - | 4.16 B | 2.44 B | 861 M | - | 1.62 B | 211 M | -228 M | - | 1.22 B | 697 M | 626 M | - | 2.58 B | 1.67 B | 617 M | - | 2.14 B | 1.08 B | -428 M | - | 6.1 B | 1.52 B | 387 M | - | 3.27 B | 1.57 B | 481 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.2 B | -428 M | 2.99 B |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
-8.24 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
-2.67 M | - | 1.35 % | $ 17.8 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-74.3 M | $ 7.12 | 1.28 % | $ 195 M | ||
|
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | ||
|
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | ||
|
BioNTech SE
BNTX
|
456 M | $ 92.95 | 0.88 % | $ 22.5 B | ||
|
AstraZeneca PLC
AZN
|
14.6 B | - | - | $ 96.9 B | ||
|
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
-24.5 M | - | 0.74 % | $ 768 M | ||
|
Compugen Ltd.
CGEN
|
31.6 M | $ 2.7 | -3.57 % | $ 252 M | ||
|
Abcam plc
ABCM
|
28.7 M | - | - | $ 4.9 B | ||
|
Galera Therapeutics
GRTX
|
-6.05 M | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
-5.59 M | - | -18.52 % | $ 27.3 M | ||
|
Affimed N.V.
AFMD
|
-110 M | - | -34.95 % | $ 21.5 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | ||
|
Celyad Oncology SA
CYAD
|
-28 M | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
-88.6 M | - | - | $ 344 M | ||
|
IMV
IMV
|
-35.1 M | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-4.77 M | - | -4.36 % | $ 27 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
-78.2 M | - | - | $ 384 M | ||
|
Gracell Biotechnologies
GRCL
|
-483 M | - | - | $ 3.37 B | ||
|
Coherus BioSciences
CHRS
|
-139 M | $ 1.69 | 4.66 % | $ 198 M | ||
|
Anika Therapeutics
ANIK
|
11.2 M | $ 14.63 | -1.68 % | $ 210 M | ||
|
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-8.47 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.49 | 2.5 % | $ 5.75 M | ||
|
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
-93.6 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 21.25 | 1.85 % | $ 2.7 B | ||
|
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B |